Myositis ossificans progressiva, left foot
ICD-10 M61.175 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, left foot.
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles, tendons, and other connective tissues. This condition is caused by mutations in the ACVR1 gene, which leads to dysregulation of bone morphogenetic proteins (BMPs) that promote bone formation. In patients with MOP, episodes of soft tissue swelling and inflammation are often followed by the development of heterotopic ossification, particularly in the muscles of the limbs. The left foot may be affected, leading to significant muscle weakness and restricted mobility. Patients may experience pain, stiffness, and decreased range of motion as the ossification progresses. Diagnosis is typically made through clinical evaluation, imaging studies such as X-rays or MRI, and genetic testing. Management focuses on symptomatic relief and physical therapy, as surgical intervention is often complicated by the risk of further ossification. Understanding the implications of this condition is crucial for effective treatment and rehabilitation.
Detailed clinical notes on symptoms, family history, and genetic testing results.
Patients presenting with unexplained muscle pain and swelling, particularly after trauma.
Rheumatologists should be aware of the genetic basis and potential for progressive symptoms.
Imaging studies and surgical notes if intervention is considered.
Patients with limited mobility due to ossification in the foot or other areas.
Orthopedic surgeons must consider the risks of surgery due to potential for further ossification.
Used for assessing functional limitations due to myositis ossificans.
Detailed evaluation of muscle strength and range of motion.
Physical therapists should document the impact of the condition on daily activities.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in soft tissues, leading to progressive muscle weakness and functional impairment.
